1. Сase Report of Acute Toxic Imatinib-induced Hepatitis in a Patient with Chronic Myeloid Leukemia, Sulfa Allergy, and Rheumatoid Arthritis
- Author
-
Larysa Zhuravlyova, Iryna Dyagil, Iryna Dmytrenko, Dmytro Lopin, Kuznetsov Igor, Nataliia Lopina, and Dmytro Hamov
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,chronic myeloid leukemia ,Internal medicine ,hemic and lymphatic diseases ,tyrosine kinase inhibitors ,medicine ,Internal Medicine ,drug induced liver disease ,neoplasms ,Hepatitis ,hormone therapy ,business.industry ,General Engineering ,Myeloid leukemia ,Imatinib ,acute liver failure ,medicine.disease ,Discontinuation ,acute toxic hepatitis ,Oncology ,imatinib ,Concomitant ,Rheumatoid arthritis ,Prednisolone ,Hormone therapy ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The introduction of imatinib has substantially changed the approaches to the therapy of chronic myeloid leukemia. However, this drug can cause hepatic failure and death in rare cases. This report describes a clinical case of acute, toxic imatinib-induced hepatitis in a 56-year-old woman with chronic myeloid leukemia and concomitant sulfa allergy and rheumatoid arthritis. The patient developed acute imatinib-induced hepatitis after three months of treatment with imatinib and three days after increasing the imatinib dosage from 400 mg per day to 600 mg per day, resolving within three months after imatinib discontinuation and prednisolone administration. This confirms the necessity of great caution during imatinib therapy and the monitoring of liver tests. Approximately 25 reports about clinical cases of imatinib-induced hepatitis have been published up to the present.
- Published
- 2018